

SPECIAL COMMUNICATION

The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey

Jenny Lam, MD, MAS, Jakub Hlávka, PhD, and Soeren Mattke, MD, DSc

Despite recent setbacks, disease-modifying treatments (DMTs) for Alzheimer disease (AD) might become available within a few years. These DMTs are likely to be used in the early stages of AD to avoid the progression to manifest dementia, which implies that a large reservoir of prevalent cases would need to be evaluated when DMTs first become available. Primary care providers (PCPs) would play a vital role in managing the patient flow to specialty care. We review the literature on diagnostic tests that could be used by PCPs and estimate the impact of different testing approaches on demand for specialty care.

While many tests have been evaluated, only the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) perform acceptably for detection of early-stage cognitive decline with sensitivities and specificities of 55% to 82% and 72% to 84%, respectively, for the MMSE; and 77% to 96% and 73% to 95%, respectively, for the MoCA. However, neither test is sufficiently specific for the AD pathology and would result in 4 to 5 false positives for each true positive. Blood-based tests for AD biomarkers may soon become available for clinical use. A plasma amyloid- β (A β) test has been shown to have a sensitivity of up to 97% and specificity of up to 81%. Adding this test to the MMSE or MoCA could reduce false positives by approximately 80%.

These findings suggest a combination of brief cognitive tests and blood-based biomarker tests will allow PCPs to identify patients with potential early stage AD efficiently and triage them for further evaluation. (J Am Board Fam Med 2019;32:931–940.)

Keywords: Alzheimer Disease, Amyloid Beta-Peptides, Biomarkers, Cognitive Dysfunction, Dementia, Diagnostic Tests, Disease Progression, Mental Status and Dementia Tests, Primary Health Care, Sensitivity and Specificity

Despite multiple setbacks, such as the recent termination of the clinical trial program for aducanumab, there is still hope that a disease-modifying treatment (DMT) for Alzheimer disease (AD) will become available within the next few years.¹

For example, BAN2401 was the first candidate treatment that has shown an effect on cognitive decline in a recently published Phase II trial.² These DMTs or other medications are likely to be used in the early stages of AD to prevent progression to manifest dementia. This preventive treatment paradigm means that a substantial number of patients would need to be evaluated, diagnosed, and treated for early-stage disease. The number of patients would be particularly large when DMTs first became available because of the large reservoir of

This article was externally peer reviewed.

Submitted 5 November 2018; revised 27 June 2019; accepted 27 June 2019.


From the Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA (JM); Price School of Public Policy, University of Southern California, Los Angeles, CA (JH); Center for Economic and Social Research, University of Southern California, Los Angeles, CA (SM).

Funding: This project was funded by Biogen Inc.

Conflict of interest: SM serves on the board of directors of Senscio Systems, Inc. and the scientific advisory board of aicure technologies, Boston Millennia Partners and Zano-Zano. He has received consulting fees from AARP, Biotronik, Bristol-Myers Squibb, and Defined Health. JL and JH report no financial conflicts of interest.

Prior Presentation: Presented in part at the 2019 Alzheimer's Association International Conference, Los Angeles, July 14–18, 2019 and at the Lausanne VI Workshop, Lausanne, Switzerland, November 13–14, 2019.

Corresponding author: Soeren Mattke, MD, DSc, Center for Economic and Social Research, University of Southern California, 635 Downey Way, VPD 505N, Los Angeles, CA 90089, (E-mail: mattke@usc.edu).

Figure 1. Biological model of Alzheimer disease.

prevalent cases. A recent study has shown that the US health care system is ill prepared to meet this demand because of a lack of specialists and diagnostic and treatment centers.³ Estimated wait times of up to 19 months could potentially lead to around 2.1 million patients progressing to Alzheimer's dementia while waiting for treatment. Even in the absence of a treatment, the demand for diagnostic evaluation of cognitive impairment will increase with population ageing and emerging evidence that a correct diagnosis alone changes clinical management.^{4,5}

Situated early in the care pathway, primary care providers will play a vital role in managing the patient flow to specialty care, as they will be responsible for triaging patients for further evaluation. To carry out this responsibility, primary care providers need proper tools, guidance, time, and reimbursement. This article will focus on the tools for the evaluation of cognitive impairment in the primary care setting. We present an overview of the pathobiology of AD, the DMTs in development and the diagnostic process with an emphasis on diagnostic tools for primary care providers, and simulate the impact of different approaches to the initial evaluation in the primary care setting on demand for specialty evaluation and treatment.

Pathobiology of AD

AD is a progressive neurodegenerative disease that is the most common cause of dementia in the United States, where the estimated prevalence of Alzheimer's dementia is 14.5% in adults over 65 years old.⁶ Amyloid- β (A β) plaques and neurofibrillary tangles of τ protein are the cardinal pathologic features that distinguish AD from other etiologies of dementia. The amyloid hypothesis (Figure 1) states that A β plaques, which can be detected by positron emission tomography (PET) scan with the Pittsburgh B (PiB) radiotracer (also known as the PiB-PET scan) or testing for A β


levels in cerebrospinal fluid (CSF), build up in the brain due to an imbalance of A β production and clearance. They contribute to the formation of neurofibrillary tangles of τ protein and other downstream processes that eventually lead to neuronal death.⁷ As more neurons die, the patient will start exhibiting cognitive impairment. While the core clinical manifestation of AD is episodic memory impairment, other cognitive domains may also be affected, especially as the disease progresses.^{8,9}

The diagnosis of AD is based on its biological hallmarks, and patients are classified into 3 stages based on clinical presentation: preclinical AD, mild cognitive impairment (MCI) due to AD, and Alzheimer's dementia (Figure 2).⁹ During the preclinical stage, there is no perceptible cognitive impairment, but changes in biomarkers, such as A β , are detectable by CSF testing and imaging. This preclinical stage may precede cognitive impairment by as much as 20 years.^{10,11} The next stage of AD is characterized by MCI that is detectable with neuropsychological exams; day-to-day occupational and social functioning are mostly preserved.^{8,12,13} The final stage of AD is dementia, which can be further subclassified into mild, moderate, and severe depending on the impact on activities of daily living.⁹

Disease-Modifying Treatments in Development

Disease-modifying treatments (DMTs) target the pathogenic pathway of AD to delay the onset or progression of dementia. Unlike currently available symptomatic treatments, they need to be initiated before the development of moderate-to-severe dementia, implying a need to identify patients early in the disease process.

The DMTs in these active clinical trials (Table 1)^{14–23} target either the amyloid or τ -pathogenic pathways, but there are drugs with other mechanisms of action in the earlier stages of development.^{24,25} The earliest expected primary completion date for Phase III trials is in July 2022,

Figure 2. Classification of patients in Alzheimer disease. MCI, mild cognitive impairment.

which suggests that DMTs may become commercially available as early as 2023.

Diagnostic Evaluation of Mild Cognitive Impairment

As the 2018 American Academy of Neurology guideline recommends, establishing a diagnosis of mild cognitive impairment (MCI) through validated tests is important because clinicians could provide important care through counseling, management of modifiable risks and nonpharmacological treatments, even in the absence of a DMT.²⁶

The diagnostic process to evaluate cognitive function starts with short cognitive tests to detect or confirm early-stage impairment, most likely in

primary care settings. Primary care providers might additionally look for alternative causes for the impairment and complicating factors that may affect the management of the patient, such as depression, cerebrovascular disease and medication and alcohol use. They would also document family history and potentially assess genetic risk.

Confirmatory diagnostic testing of MCI and identification of the underlying pathology will likely require the expertise of dementia specialists because of the complexity of the required tests and the differential diagnosis. A comprehensive neuropsychological test battery may be performed by specialists to verify and detail the degree and pattern of the cognitive impairment. Biomarker test-

Table 1. Disease-Modifying Treatments for Alzheimer's Disease in Phase 2 and Phase 3 Clinical Trials

Candidate	Clinical Trial Phase	Expected Primary Completion Date	National Clinical Trial Identifier
Anti-A β antibodies			
Gantenerumab	Phase 3	May-22	NCT03443973, NCT03444870
BAN2401	Phase 3	Jul-22	NCT03887455
LY3002813	Phase 2	Oct-20	NCT03367403
Anti-tau antibodies			
ABBV-8E12	Phase 2	Dec-20	NCT02880956
RO7105705	Phase 2	Sep-20	NCT03289143
BACE inhibitors			
Elenbecestat (E2609)	Phase 3	Jun-21	NCT03036280
CNP520	Phase 2/3	Jul-24	NCT03131453
Vaccines			
CAD106	Phase 2/3	Aug-24	NCT02565511
AADvac1	Phase 2	Jun-19	NCT02579252

A β , amyloid-beta; BACE, Beta-secretase.

Clinical trial information was obtained from ClinicalTrials.gov as of June 27, 2019.

ing with either CSF analysis or PET imaging can be done to diagnose AD as the underlying etiology, but both tests are typically not yet available or covered outside of clinical research.⁸ Cases with mixed etiology can present with a complex pattern of symptoms and biomarker and imaging findings. Furthermore, patients with MCI may remain stable or revert to normal cognition in some cases. Given these variabilities and complexities in the disease presentation, specialists are better equipped to sort out these clinical and biomarker findings to work through the differential diagnoses and, should a DMT become available, assess the patient for treatment indications. Because specialist evaluation is complex, costly, and capacity constrained, optimizing evaluation at the primary care level is critical to reduce wait times.

Brief Cognitive Tests for MCI

Organizations like the Alzheimer's Association²⁷ and the Gerontological Society of America²⁸ are recommending various screening tests, such as the General Practitioner Assessment of Cognition and the Mini-Cog, to be used, for example, for cognitive assessment as part of the Annual Wellness Visit. These instruments have been validated for detection of dementia but not of MCI.^{29–31}

Beyond the General Practitioner Assessment of Cognition and Mini-Cog, there are a number of cognitive tests that have been proposed for evaluating MCI, but—similar to previous reviews—we found limited evidence supporting the use of most of these cognitive tests.^{29–33} The best researched and most widely used tests in the United States to date are the mini-mental state examination (MMSE) and the Montreal Cognitive Assessment (MoCA). These tests are potentially suitable for use in primary care settings; as they take only approximately 10 to 15 minutes to administer and score without the need for dedicated equipment or specially trained personnel. They test multiple cognitive domains, but differ in how each of the domains are weighted (Table 2), which may influence their performance in detecting MCI.³⁴

MMSE

The MMSE was originally developed to assess the cognitive function of elderly, hospitalized patients with a wide range of health conditions, not specific for dementia.³⁵ There is considerable variability in the reported diagnostic performance of the MMSE

Table 2. Comparison of the Scoring of Cognitive Domains by the MMSE and MoCA

Cognitive Domain	MMSE (Maximum Score)	MoCA (Maximum Score)
Orientation: time and place	10	6
Registration	3	—
Attention and concentration	5	6
Memory	3	5
Verbal fluency	—	1
Language	8	5
Visuospatial abilities	1	5
Abstraction	—	2
Total score	30	30

MMSE, Mini-Mental State Exam; MoCA, Montreal Cognitive Assessment.

for MCI and dementia due to the heterogeneity of the patient samples, the cutoff scores, and the diagnostic criteria.^{29,31,36} Systematic reviews have reported that the MMSE performs relatively well in identifying possible Alzheimer's dementia, but its ability to detect MCI has been found to be suboptimal.^{29,31}

There are several possible reasons for the limited performance of the MMSE to detect MCI: The memory and executive functioning tasks are underrepresented, and the score is sensitive to the literacy and education level of the patient.^{31,37,38} Furthermore, MMSE has a narrow dynamic performance range for normal individuals, creating a ceiling effect that limits the discrimination between high-scoring MCI patients and cognitively normal individuals.^{31,39,40}

MoCA

In contrast to MMSE, MoCA was developed specifically to detect MCI^{29,40} and addresses some of the shortcomings of MMSE.³⁹ It includes more complex tasks, including its test of executive function, which helps mitigate the ceiling effect.³⁹ Although education still affects MoCA scores, MoCA tries to address the issue by adding 1 point to the scores of patients who have 12 or fewer years of education.^{32,40}

In its original validation study, MoCA performed better than the MMSE at distinguishing MCI from normal cognition,⁴⁰ and its psychometric properties have since been further validated.^{29,31,41,42} Studies that directly compared the

abilities of the MMSE and MoCA for distinguishing MCI from normal cognition reported sensitivities of 55% to 82% and specificities of 72% to 84% for the MMSE,^{43–49} and sensitivities of 77% to 96% and specificities of 73% to 95% for the MoCA. Meta-analyses have further suggested that MoCA may be the best MCI screening test available.^{30,32}

Newer Cognitive Tests

The mini-Addenbrooke's cognitive examination (m-ACE)^{34,50,51} may have equivalent or even a slightly improved performance than the MMSE and MoCA, but as a newer test, it is not as well validated.

Computerized cognitive tests have been developed, and once they are better validated, they may improve the convenience of cognitive screening and allow the collection of additional clinical variables, such as response time and eye-movement, and facilitate detection of cognitive changes over time.^{52–56}

Laboratory Tests

As cognitive screening tests have limited specificity for different etiologies of MCI, and PiB-PET scan and CSF testing are too expensive and invasive, respectively, for use as screening tools, blood tests with reasonable specificity for the AD pathology could improve the efficiency of the evaluation process in the primary care setting.

So far, there is no blood test for biomarkers indicative of AD pathology. Several plasma biomarkers that are specific to the AD pathology, such as A β and tau, or indicative of nonspecific neuronal injury, such as neurofilament light chain are in development, and others are being explored.^{57–62} Similar to CSF biomarkers,⁸ plasma biomarkers may be most useful when used in combination.

A β

Developing an A β blood test for routine clinical use proved to be challenging because of the low concentration of A β in plasma, the peripheral production of A β by platelets and the binding of A β to plasma proteins.⁶³ In addition, sample storage and processing can affect the quality and reproducibility of the results.⁶⁴

While early studies of plasma A β levels had inconsistent results,^{65,66} more recent studies were more promising: Nakamura et al,⁶⁷ for example,

reported a sensitivity of 97% and a specificity of 81%, suggesting that a test for routine clinical use might become available in the foreseeable future.^{67–69}

Tau

Changes in CSF tau levels seem later than changes in CSF A β levels, but there may still be a role for blood-based tau testing, as plasma tau levels correlate with AD, CSF tau levels, A β and tau deposition in the brain as detected by PET imaging, and cortical thickness.^{66,70,71} Substantial development work remains necessary before a plasma-based tau test will become available.⁷²

Neurofilament Light Chain

As a biomarker for nonspecific neuronal injury, plasma neurofilament light chain (NfL) testing may have value when used in combination with plasma A β and tau testing. The correlation between plasma and CSF NfL levels is better than the correlation of plasma and CSF tau levels.⁷⁰ Plasma NfL levels are also higher in A β -positive patients than in A β -negative patients.⁷³ Plasma NfL tests are today mostly used in research.

Alternative Diagnostic Modalities in Development

There are other diagnostic modalities in earlier stages of research. Retinal scans that measure A β deposition in the retina are currently in various stages of clinical trials in the US, Europe, and Australia.⁷⁴ An earlier study had shown that retinal A β plaque burden correlates with central nervous system (CNS) A β plaque burden.⁷⁵ Since abnormal speech patterns and eye movements are potential signs of AD, automated tools and computational techniques are being developed to analyze speech and eye movement recordings.^{76–78} Some researchers are studying olfactory dysfunction in AD,^{79–81} while others are analyzing electroencephalography patterns.^{82–84}

Impact on Downstream Patient Caseloads

Based on US Census projections, there will be 98.8 million individuals 55 years and older in 2020.⁸⁵ Extrapolating from published prevalence estimates, 10.7 million of these individuals will have MCI.^{26,88} Of the individuals with MCI, 6.6 million of them will have evidence of A β deposition in the brain.¹²

Using published sensitivities and specificities,⁴⁵ cognitive testing of this general population with the

Table 3. Projected Impact of Diagnostic Testing on Demand for Specialty Evaluation

Test for MCI Due to AD	False Positives (in Millions)	True Positives (in Millions)	Number of Patients Requiring Specialty Referral (in Millions)	Proportion of Referred Patients with Confirmed MCI Due to AD
MMSE	27.1	5.4	32.6	17%
MMSE + plasma A β	5.2	5.3	10.4	51%
MoCA	21.9	5.6	27.5	20%
MoCA + plasma A β	4.2	5.4	9.6	56%

A β , amyloid-beta; AD, Alzheimer disease; MCI, mild cognitive impairment; MMSE, mini-mental state exam; MoCA, Montreal Cognitive Assessment.

Patients with MCI due to AD have both MCI and evidence of A β deposition in the brain. We estimated that 10.7 million people in the 55+-year-old population in the United States in 2020 will have MCI. Of these, 6.6 million will also have evidence of A β deposition.

MMSE alone would identify 5.4 million true-positive individuals with MCI due to AD (ie, have both MCI and A β deposition) and 27.1 million false-positive individuals. Based on the sensitivity and specificity of plasma A β testing reported by Nakamura et al,⁶⁷ the sequential addition of plasma A β testing of the individuals who showed MCI on the MMSE could potentially reduce the number of false-positive cases to 5.2 million, while still detecting 5.3 million true-positive patients. Similarly, cognitive testing with MoCA⁴⁵ alone would identify 5.6 million true-positive MCI due to AD patients and 21.9 million false-positive patients. MoCA, followed by plasma A β testing,⁶⁷ would identify 5.4 million true-positive patients and 4.2 million false-positive patients.

The results (Table 3) shows how the MMSE will result in 5 false-positive cases for every 1 true-positive case detected. Replacing the MMSE with the MoCA will reduce the ratio to 4 false-positive cases for every 1 true-positive case detected. The addition of plasma A β testing might reduce the ratio of false to true-positive cases to about 1 to 1. In other words, it might prevent approximately 80% of the false-positive cases based on MMSE or MoCA testing from getting unnecessarily specialist referrals for confirmatory diagnosis.

Discussion

In our review of effective and efficient tools that could aid primary care providers to detect MCI due to AD, we found that a large number of cognitive tests and other modalities exist but also that their utility is not well supported. Most of the cognitive tests are either not usable in primary care settings because of their length and complexity, or not well

validated, or perform poorly for the detection of MCI.^{29–32} So far, only the MMSE and the MoCA have been shown to combine acceptable diagnostic accuracy and suitability for administration in primary care.

While cognitive tests perform reasonably well in determining the degree and pattern of cognitive impairment, they are inherently limited in their ability to identify the underlying etiology. A variety of diagnostic modalities attempt to differentiate the underlying etiology without expensive PiB-PET scans or invasive CSF testing, but none of them have been approved for clinical use yet. Currently, the most promising modalities are plasma biomarker tests, such as for A β , τ , and NfL.^{65,67–71,73} While there have been technological challenges to developing these tests, recent studies demonstrated promising results and suggest that they will be available for routine clinical use in the future, possibly in combination with each other or some of the other biomarkers in development.^{57–62}

Our calculations underscore that a combination of cognitive testing and plasma biomarkers is probably necessary for efficient testing for MCI due to AD in primary care settings. Both the MMSE and the MoCA when used alone would result in 4 to 5 false positives for every 1 true-positive case. The addition of plasma A β testing would eliminate approximately 80% of these false-positive cases, reducing the number of patients who would require specialty referral by more than two-thirds. Our findings thus highlight the importance of having a reliable plasma biomarker test, especially since there is a shift toward a biological definition of AD from the historic clinical one.⁸⁷

The aging US population coupled with the large reservoir of prevalent cases that would require evaluation when a DMT for AD is first approved imply a critical role for primary care providers, as they will have to prioritize patients with the greatest likelihood of benefiting from treatment for specialist visits. Intensified efforts to improve cognitive screening tools and to develop plasma biomarkers for routine use are dearly needed to enable primary care providers to play that critical role.

To see this article online, please go to: <http://jabfm.org/content/32/6/931.full>.

References

- Selkoe DJ. Alzheimer disease and aducanumab: adjusting our approach. *Nat Rev Neurol* 2019;15:365–366.
- EISAI and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease At Alzheimer's Association International Conference (AAIC) 2018 [Press Release]. Eisai Co., Ltd. and Biogen Inc., July 26 2018.
- Liu JL, Hlávka JP, Hillestad R, Mattke S. Assessing the preparedness of the U.S. health care system infrastructure for an Alzheimer's treatment. Santa Monica, CA: RAND Corporation; 2017.
- Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. *JAMA* 2019;321:1286–1294.
- Cognat E, Mouton Liger F, Troussière AC, et al. What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. *BMJ Open* 2019;9(5):e026380.
- Rajan KB, Weuve J, Barnes LL, Wilson RS, Evans DA. Prevalence and incidence of clinically diagnosed Alzheimer's disease dementia from 1994 to 2012 in a population study. *Alzheimers Dement* 2019;15:1–7.
- Lane CA, Hardy J, Schott JM. Alzheimer's disease. *Eur J Neurol* 2018;25:59–70.
- Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011;7:270–279.
- McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011;7:263–269.
- Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011;7:280–292.
- Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurol* 2013;12:207–216.
- Petersen RC, Aisen P, Boeve BF, et al. Mild cognitive impairment due to Alzheimer disease in the community. *Ann Neurol* 2013;74:199–208.
- Knopman DS, Petersen RC. Mild cognitive impairment and mild dementia: a clinical perspective. *Mayo Clin Proc* 2014;89:1452–1459.
- Safety and Efficacy study of gantenerumab in participants with early Alzheimer's disease (AD). Available from: <https://ClinicalTrials.gov/show/NCT03443973>. Accessed March 17, 2019.
- Efficacy and Safety study of gantenerumab in participants with early Alzheimer's disease (AD). Available from: <https://ClinicalTrials.gov/show/NCT03444870>. Accessed March 17, 2019.
- A study to confirm safety and efficacy of BAN2401 in participants with early Alzheimer's disease. Available from: <https://ClinicalTrials.gov/show/NCT03887455>. Accessed June 22, 2019.
- A study of LY3002813 in participants with early symptomatic Alzheimer's disease (TRAILBLAZER-ALZ). Available from: <https://ClinicalTrials.gov/show/NCT03367403>. Accessed March 17, 2019.
- A study to evaluate the efficacy and safety of ABBV-8E12 in subjects with early Alzheimer's disease. Available from: <https://ClinicalTrials.gov/show/NCT02880956>. Accessed March 17, 2019.
- A study to evaluate the efficacy and safety of RO7105705 in patients with prodromal to mild Alzheimer's disease. Available from: <https://ClinicalTrials.gov/show/NCT03289143>. Accessed March 17, 2019.
- A 24-month study to evaluate the efficacy and safety of E2609 in subjects with early Alzheimer's disease_ (MissionAD2). Available from: <https://ClinicalTrials.gov/show/NCT03036280>. Accessed March 17, 2019.
- A study of CNP520 versus placebo in participants at risk for the onset of clinical symptoms of Alzheimer's disease. Available from: <https://ClinicalTrials.gov/show/NCT03131453>. Accessed March 17, 2019.
- A study of CAD106 and CNP520 versus placebo in participants at risk for the onset of clinical symptoms of Alzheimer's disease. Available from: <https://ClinicalTrials.gov/show/NCT02565511>. Accessed March 17, 2019.
- 24 months safety and efficacy study of AADvac1 in patients with mild Alzheimer's disease. Available from: <https://ClinicalTrials.gov/show/NCT02579252>. Accessed March 17, 2019.

24. Cummings J, Lee G, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2018. *Alzheimers Dement* (N Y) 2018;4:195–214.
25. Khan A, Corbett A, Ballard C. Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets. *Expert Rev Neurother* 2017;17:683–695.
26. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: mild cognitive impairment: report of the Guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. *Neurology* 2018;90:126–135.
27. Cordell CB, Borson S, Boustani M, et al. Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. *Alzheimers Dement* 2013;9:141–150.
28. Gerontological Society of America (GSA) workgroup on cognitive impairment detection and earlier diagnosis. KAER—A 4-step process to detecting cognitive impairment and earlier diagnosis of dementia. Available from: <https://www.geron.org/images/gsa/kaer/gsa-kaer-toolkit.pdf>. Published 2017. Accessed March 3, 2019.
29. Lin JS, O'Connor E, Rossom RC, et al. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. In: Screening for cognitive impairment in older adults: an evidence update for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013.
30. Tsoi KK, Chan JY, Hirai HW, Wong SY, Kwok TC. Cognitive tests to detect dementia: a systematic review and meta-analysis. *JAMA Intern Med* 2015;175:1450–1458.
31. Lonie JA, Tierney KM, Ebmeier KP. Screening for mild cognitive impairment: a systematic review. *Int J Geriatr Psychiatry* 2009;24:902–915.
32. Ozer S, Young J, Champ C, Burke M. A systematic review of the diagnostic test accuracy of brief cognitive tests to detect amnesic mild cognitive impairment. *Int J Geriatr Psychiatry* 2016;31:1139–1150.
33. Weissberger GH, Strong JV, Stefanidis KB, Summers MJ, Bondi MW, Stricker NH. Diagnostic accuracy of memory measures in Alzheimer's dementia and mild cognitive impairment: a systematic review and meta-analysis. *Neuropsychol Rev* 2017;27:354–388.
34. Williamson JC, Larner AJ. MACE for the diagnosis of dementia and MCI: 3-year pragmatic diagnostic test accuracy study. *Dement Geriatr Cogn Disord* 2018;45:300–307.
35. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975;12:189–198.
36. Folstein M, Folstein S. Invited reply to "The death knoll for the MMSE: has it outlived its purpose?". *J Geriatr Psychiatry Neurol* 2010;23:158–159.
37. Carnero-Pardo C. Should the mini-mental state examination be retired? *Neurologia* 2014;29:473–481.
38. Nieuwenhuis-Mark RE. The death knoll for the MMSE: has it outlived its purpose? *J Geriatr Psychiatry Neurol* 2010;23:151–157.
39. Trzepacz PT, Hochstetler H, Wang S, Walker B, Saykin AJ. Relationship between the Montreal Cognitive Assessment and Mini-Mental State Examination for assessment of mild cognitive impairment in older adults. *BMC Geriatr* 2015;15:107.
40. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005;53:695–699.
41. Julayanont P, Brousseau M, Chertkow H, Phillips N, Nasreddine ZS. Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer's disease. *J Am Geriatr Soc* 2014;62:679–684.
42. Lam B, Middleton LE, Masellis M, et al. Criterion and convergent validity of the Montreal Cognitive Assessment with screening and standardized neuropsychological testing. *J Am Geriatr Soc* 2013;61:2181–2185.
43. Mellor D, Lewis M, McCabe M, et al. Determining appropriate screening tools and cut-points for cognitive impairment in an elderly Chinese sample. *Psychol Assess* 2016;28:1345–1353.
44. Luis CA, Keegan AP, Mullan M. Cross validation of the Montreal Cognitive Assessment in community dwelling older adults residing in the Southeastern US. *Int J Geriatr Psychiatry* 2009;24:197–201.
45. Roalf DR, Moberg PJ, Xie SX, Wolk DA, Moelter ST, Arnold SE. Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging. *Alzheimers Dement* 2013;9:529–537.
46. Ciesielska N, Sokołowski R, Mazur E, Podhorecka M, Polak-Szabela A, Kedziora-Kornatowska K. Is the Montreal Cognitive Assessment (MoCA) test better suited than the Mini-Mental State Examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis. *Psychiatr Pol* 2016;50:1039–1052.
47. Freitas S, Simões MR, Alves L, Santana I. Montreal cognitive assessment: validation study for mild cognitive impairment and Alzheimer disease. *Alzheimer Dis Assoc Disord* 2013;27:37–43.
48. Fujiwara Y, Suzuki H, Yasunaga M, et al. Brief screening tool for mild cognitive impairment in older Japanese: validation of the Japanese version of the Montreal Cognitive Assessment. *Geriatr Gerontol Int* 2010;10:225–232.
49. Tiffin-Richards FE, Costa AS, Holschbach B, et al. The Montreal Cognitive Assessment (MoCA)—A sensitive screening instrument for detecting cogni-

- tive impairment in chronic hemodialysis patients. *PLoS One* 2014;9(10):e106700.
50. Hsieh S, McGrory S, Leslie F, et al. The Mini-Addenbrooke's Cognitive Examination: a new assessment tool for dementia. *Dement Geriatr Cogn Disord* 2015;39:1–11.
 51. Larner AJ. MACE versus MoCA: equivalence or superiority? Pragmatic diagnostic test accuracy study. *Int Psychogeriatr* 2017;29:931–937.
 52. Berg JL, Durant J, Léger GC, Cummings JL, Nasreddine Z, Miller JB. Comparing the electronic and standard versions of the Montreal Cognitive Assessment in an outpatient memory disorders clinic: a validation study. *J Alzheimers Dis* 2018;62:93–97.
 53. Wild K, Howieson D, Webbe F, Seelye A, Kaye J. Status of computerized cognitive testing in aging: a systematic review. *Alzheimers Dement* 2008;4:428–437.
 54. Darby DG, Fredrickson J, Pietrzak RH, Maruff P, Woodward M, Brodtmann A. Reliability and usability of an internet-based computerized cognitive testing battery in community-dwelling older people. *Computers Human Behav* 2014;30:199–205.
 55. Buckley RF, Sparks KP, Papp KV, et al. Computerized cognitive testing for use in clinical trials: a comparison of the NIH Toolbox and Cogstate C3 batteries. *J Prev Alzheimers Dis* 2017;4:3–11.
 56. Denboer JW, Nicholls C, Corte C, Chestnut K. National Institutes of Health Toolbox Cognition Battery. *Arch Clin Neuropsychol* 2014;29:692–694.
 57. Yang H, Lyutvinskiy Y, Herukka SK, Soininen H, Rutishauser D, Zubarev RA. Prognostic polypeptide blood plasma biomarkers of Alzheimer's disease progression. *J Alzheimers Dis* 2014;40:659–666.
 58. Hye A, Riddoch-Contreras J, Baird AL, et al. Plasma proteins predict conversion to dementia from prodromal disease. *Alzheimers Dement* 2014;10:799–807.e792.
 59. DeMarshall CA, Nagele EP, Sarkar A, et al. Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers. *Alzheimers Dement (Amst)* 2016;3:51–62.
 60. Yamamoto-Imoto H, Zamolodchikov D, Chen ZL, et al. A novel detection method of cleaved plasma high-molecular-weight kininogen reveals its correlation with Alzheimer's pathology and cognitive impairment. *Alzheimers Dement (Amst)* 2018;10:480–489.
 61. Varma VR, Varma S, An Y, et al. Alpha-2 macroglobulin in Alzheimer's disease: a marker of neuronal injury through the RCAN1 pathway. *Mol Psychiatry* 2017;22:13–23.
 62. Zarrouk A, Debbabi M, Bezine M, et al. Lipid biomarkers in Alzheimer's disease. *Curr Alzheimer Res* 2018;15:303–312.
 63. Chintamaneni M, Bhaskar M. Biomarkers in Alzheimer's disease: a review. *ISRN Pharmacol* 2012;2012:984786.
 64. Donohue MC, Moghadam SH, Roe AD, et al. Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. *Alzheimers Dement* 2015;11:1069–1079.
 65. Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. *Lancet Neurol* 2016;15:673–684.
 66. Ritchie C, Smailagic N, Noel-Storr AH, et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). *Cochrane Database Syst Rev* 2014(6):Cd008782.
 67. Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid- β biomarkers for Alzheimer's disease. *Nature* 2018;554:249–254.
 68. Fandos N, Perez-Grijalba V, Pesini P, et al. Plasma amyloid beta 42/40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals. *Alzheimers Dement (Amst)* 2017;8:179–187.
 69. Tzen KY, Yang SY, Chen TF, et al. Plasma A β but not tau is related to brain PiB retention in early Alzheimer's disease. *ACS Chem Neurosci* 2014;5:830–836.
 70. Blennow K. A review of fluid biomarkers for Alzheimer's disease: moving from CSF to blood. *Neurol Ther* 2017;6(Suppl 1):15–24.
 71. Mielke MM, Hagen CE, Xu J, et al. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. *Alzheimers Dement* 2018;14:989–997.
 72. Chen Z, Mengel D, Keshavan A, et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease. *Alzheimers Dement* 2019;15:487–496.
 73. Mattsson N, Andreasson U, Zetterberg H, Blennow K. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. *JAMA Neurol* 2017;74:557–566.
 74. Abbasi J. A retinal Scan for Alzheimer disease. *JAMA* 2017;318:1314.
 75. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, et al. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. *NeuroImage* 2011;54(Suppl 1):S204–S217.
 76. Garrard P, Nemes V, Nikolic D, Barney A. Motif discovery in speech: application to monitoring Alzheimer's disease. *Curr Alzheimer Res* 2017;14:951–959.
 77. Khodabakhsh A, Demiroglu C. Analysis of speech-based measures for detecting and monitoring Alzheimer's disease.

- mer's disease. *Methods Mol Biol* 2015;1246:159–173.
78. Beltrán J, Garcia-Vazquez MS, Benois-Pineau J, Gutierrez-Robledo LM, Dartigues JF. Computational techniques for eye movements analysis towards supporting early diagnosis of Alzheimer's disease: A Review. *Comput Math Methods Med* 2018; 2018:2676409.
79. Silva MME, Mercer PBS, Witt MCZ, Pessoa RR. Olfactory dysfunction in Alzheimer's disease systematic review and meta-analysis. *Dement Neuropsychol* 2018;12:123–132.
80. Jung HJ, Shin IS, Lee JE. Olfactory function in mild cognitive impairment and Alzheimer's disease: A meta-analysis. *Laryngoscope* 2019;129:362–369.
81. Velayudhan L. Smell identification function and Alzheimer's disease: a selective review. *Curr Opin Psychiatry* 2015;28:173–179.
82. Horvath A, Szucs A, Csukly G, Sakovics A, Stefanics G, Kamondi A. EEG and ERP biomarkers of Alzheimer's disease: a critical review. *Front Biosci (Landmark Ed)* 2018;23:183–220.
83. Nobukawa S, Yamanishi T, Nishimura H, Wada Y, Kikuchi M, Takahashi T. Atypical temporal-scale-specific fractal changes in Alzheimer's disease EEG and their relevance to cognitive decline. *Cogn Neurodyn* 2019;13:1–11.
84. Kanda PAM, Oliveira EF, Fraga FJ. EEG epochs with less alpha rhythm improve discrimination of mild Alzheimer's. *Computer methods and programs in biomedicine* 2017;138:13–22.
85. U.S. Census Bureau, Population Division. Projected 5-Year Age Groups and Sex Composition: Main Projections Series for the United States, 2017–2060. Available from: <https://www.census.gov/data/tables/2017/demo/popproj/2017-summary-tables.html>. Accessed January 31, 2019.
86. Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. *Lancet* 2006;367:1262–1270.
87. Will Europe be ready for the treatment of Alzheimer's disease? *Lancet Neurol* 2018;17:1025.